Delivering Personalized Oncology

Systems Biology enabled individualized risk assessment and therapy matching.

Systems approach to personalized medicine

A systems approach will enable “patient-centric” paradigm for personalized, precision oncology.

Sygnomics uses SYstems Genetic Network AnaLysis (SYGNAL) technology to accurately predict risk of disease progression and rank prioritize therapies that target specific cancer-driving gene networks in an individual patient.

Current State of Precision Oncology (2021)

~1.8M new diagnosis

~183B in therapy expenditure

~20,000 Oncologists

<10%

Proportion of cancer mutations that are actionable

>75%

Failure rate of FDA-approved cancer therapies

98%

Failure rate of oncology clinical trials

SYGNOMICS Services

“The SYGNOMICS Precision Oncology platform uses systems biology and white-box machine learning to generate predictive, interpretable, and actionable, patient-specific blueprints.”

-Dr. Nitin S Baliga

Our Approach

“Our proven approach individualizes risk assessment and will help you discover new targets, drugs, and drug combinations specifically matched to tumor characteristics of patients.”

-Dr. Anoop Patel

Our Services

Risk Prediction

Dynamic individualized assessment of disease progression risk

Learn More

Therapy Matching

Prioritize therapies for a patient based on an individualized activity assessment of disease-associated genetic programs.

Learn More

Science and Clinical Partners

Testimonials

This is an incredibly useful tool! I don’t know of any tool like this that oncologists can use to effortlessly explore evidence from disparate sources, all put into the context of risk probability and therapies matched to the molecular characteristics of a single patient. I foresee enormous value for this tool as a subscription service for at least three types of customers: clinical researchers, oncologists and even patients.

David Coffey, M.D., University of Miami

News

Sygnomics lands $2 million grant to advance personalized precision oncology solutions.

sygnomics_adm2023-10-18T22:38:59+00:00October 18th, 2023|

The Andy Hill Cancer Research Endowment (CARE) Fund awarded a $2 million Life Science Startup Catalyst grant to SYGNOMICS, a personalized precision oncology startup that helps oncologists improve patient outcomes by accurately predicting

SYGNAL used to characterize treatment-induced evolution of tumor cell states in a single patient

sygnomics_adm2023-01-17T20:09:56+00:00January 17th, 2023|

Glioblastoma (GBM) is a heterogeneous tumor made up of cell states that evolve over time. Here, we modeled tumor evolutionary trajectories during standard-of-care treatment using multi-omic single-cell analysis of a primary tumor sample,

Sygnomics and xCures present at 2021 SNO Annual Meeting

sygnomics_adm2023-01-17T18:27:00+00:00November 20th, 2022|

Sygnomics in collaboration with xCures presented a poster at 2021 SNO Annual Meeting to demonstrate how systems biology-based predictive cancer models for GBM in combination with real-world data registry can help decision-making and